Opinion|Videos|June 24, 2024

Monitoring Treatment Response

Author(s)Brian Helfand, MD, PhD, Gordon A. Brown, DO, Adam Scott Feldman, MD, MPH

A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.

Episodes in this series

A panel of 4 experts on prostate cancer

EP. 1 Overview of Advances in Imaging in Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 2 The Impact of PSMA-PET Imaging in Prostate Cancer

A panel of experts on prostate cancer

EP. 3 Identifying the Right Patient Population for PSMA-PET Imaging

A panel of 4 experts on prostate cancer

EP. 4 PSMA-PET Imaging in the Biochemical Recurrence Setting

A panel of 4 experts on prostate cancer

EP. 5 The Impact of PSMA-PET Imaging on Treatment Decisions

A panel of 4 experts on prostate cancer

EP. 6 The Role for PSMA-PET Imaging in Active Surveillance

A panel of 4 experts on prostate cancer

EP. 7 When and How Often PSMA-PET Imaging Should be Used

A panel of 4 experts on prostate cancer

EP. 8 Monitoring Treatment Response

A panel of 4 experts on prostate cancer

EP. 9 Unmet Needs and Challenges in Imaging of Prostate Cancer

A panel of 4 experts on prostate cancer

EP. 10 The Value of Multidisciplinary Care in PSMA-PET Imaging

A panel of 4 experts on prostate cancer

EP. 11 Future Directions in PSMA-PET Imaging

Tony Abraham, DO, MPA, a nuclear radiologist

EP. 12 PSMA-PET Imaging for Prostate Cancer: Perspectives From a Nuclear Radiologist

Tony Abraham, DO, MPA, a nuclear radiologist

EP. 13 Similarities and Differences Among PSMA-PET Tracers

Tony Abraham, DO, MPA, a nuclear radiologist

EP. 14 Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging Results

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

ByLorelei A. Mucci, ScD, MPH

September 11th 2026

Doublet or triplet? Urologists weighs in on mCSPC options

ByUrology Times staff

September 10th 2026

Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD

ByMartin Schoen, MD, PhD,Hannah Clarke

September 10th 2026

App-based intervention aims to increase PSA screening among Black men

ByHannah Clarke

September 9th 2026

The critical role of advocacy in urologic oncology

ByRuchika Talwar, MD,Lan Anh Galloway, MD

September 9th 2026

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

AI-generated profiles impersonate female urologists to market ED products online

The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH

Doublet or triplet? Urologists weighs in on mCSPC options

John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC

Alternative BCG strains may help address ongoing supply challenges in NMIBC